Furthermore, the combination of anti-PI3K/AKT signaling agents with other conventional anti-tumor drugs may represent a new direction to overcome the intracellular escape mechanisms of conventional chemotherapies and increase chemosensitivity in patients with USC16[27,28]. Here, AKT1 is linked to neoplasm.